MADRID, 10 Ago. (EUROPA PRESS) –
The Danish pharmaceutical Novo Nordisk registered a net profit of 39,242 million crowns (5,266 million euros) in the first half of 2023, which represents an increase of 42.5% compared to the result recorded in the same period of 2023, as reported the company, which has revised its annual forecasts upwards given the expectation of growth in sales of drugs against diabetes and obesity.
In the first six months of the year, Novo Nordisk’s net sales totaled 107,667 million crowns (14,448 million euros), 29.2% more than in the same period of the previous year, including a 367% growth in sales from Wegovy, up to 12,081 million crowns (1,621 million euros).
Between April and June, the Danish laboratory obtained a net profit of 19,428 million crowns (2,607 million euros), 46% more, while sales grew 32%, to 54,300 million crowns (7,287 million euros).
“We are very pleased with the sales growth in the first half of 2023,” said Lars Fruergaard Jorgensen, Chairman and CEO of Novo Nordisk, noting the growing demand for diabetes and obesity treatments.
In this way, the company has revised its sales growth forecasts upwards, to a range of 27% to 33% without taking into account the exchange rate, compared to the previous range of 24% to 30%.
Likewise, Novo Nordisk expects that its operating profit will increase in the year between 31% and 37%, when previously it expected an increase of 28% to 34%.
